QZQinwei Zhou

Qinwei Zhou

*This is an algorithmically generated author record based on publicly available information.

Qinwei Zhou has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Alice Matathia

    BioAnalytical Sciences; ImClone Systems Corporation; A Wholly-Owned Subsidiary of Eli Lilly and Company; Branchburg, NJ, USA

    2 shared publications
  • Babita Parekh

    BioAnalytical Sciences; ImClone Systems Corporation; A Wholly-Owned Subsidiary of Eli Lilly and Company; Branchburg, NJ, USA

    2 shared publications
  • Jingming Zhang

    BioAnalytical Sciences; ImClone Systems Corporation; A Wholly-Owned Subsidiary of Eli Lilly and Company; Branchburg, NJ, USA

    2 shared publications
  • Shanmuuga Sundaram

    BioAnalytical Sciences; ImClone Systems Corporation; A Wholly-Owned Subsidiary of Eli Lilly and Company; Branchburg, NJ, USA

    2 shared publications
  • Jun Qian

    Bioanalytical Science; ImClone Systems, a wholly owned subsidiary of Eli Lilly & Co.; Branchburg, NJ USA

    1 shared publication
  • Liangjie Tang

    BioAnalytical Sciences, ImClone Systems Corporation, Wholly-Owned Subsidiary of Eli Lilly and Company, Branchburg, NJ, USA

    1 shared publication

Latest Publications

  • Open Access

    Conformational characterization of the charge variants of a human IgG1 monoclonal antibody using H/D exchange mass spectrometry

    by Liangjie Tang, Shanmuuga Sundaram, Jingming Zhang, Ping Carlson, Alice Matathia, Babita Parekh, Qinwei Zhou, Ming-Ching Hsieh

    MAb1, a human IgG1 monoclonal antibody produced in a NS0 cell line, exhibits charge heterogeneity because of the presence of variants formed by processes such as N-terminal glutamate cyclization, C-terminal lysine truncation, deamidation, aspartate isomerization and sialylation in the carbohydrate moiety. Four major charge variants of MAb1 were isolated and the conformations of these charge variants were studied using hydrogen/deuterium exchange mass spectrometry, including the H/D exchange time course (HX-MS) and the stability of unpurified proteins from rates of H/D exchange (SUPREX) techniques. HX-MS was used to evaluate the conformation and solution dynamics of MAb1 charge variants by measuring their deuterium buildup over time at the peptide level. The SUPREX technique evaluated the unfolding profile and relative stability of the charge variants by measuring the exchange properties of globally protected amide protons in the presence of a chemical denaturant. The H/D exchange profiles from both techniques were compared among the four charge variants of MAb1. The two techniques together offered extensive understanding about the local and subglobal/global unfolding of the charge variants of MAb1. Our results demonstrated that all four charge variants of MAb1 were not significantly different in conformation, solution dynamics and chemical denaturant-induced unfolding profile and stability, which aids in understanding the biofunctions of the molecules. The analytical strategy used for conformational characterization may also be applicable to comparability studies done for antibody therapeutics.


  • An innovative approach for the characterization of the isoforms of a monoclonal antibody product

    by Shanmuuga Sundaram, Alice Matathia, Jun Qian, Jingming Zhang, Ming-Ching Hsieh, Tun Liu, Richard Crowley, Babita Parekh, Qinwei Zhou

    Protein biopharmaceuticals, such as monoclonal antibodies (mAbs) are widely used for the prevention and treatment of various diseases. The complex and lengthy upstream and downstream production methods of the antibodies make them susceptible to physical and chemical modifications. Several IgG1 immunoglobulins are used as medical agents for the treatment of colon, breast, and head and neck cancers, and at least four to eight isoforms exist in the products. The regulatory agencies understand the complex nature of the antibody molecules and allow the manufactures to set their own specifications for lot release, provided the safety and efficacy of the products are established in animal models prior to clinical trials. During the manufacture of a mAb product, we observed lot-to-lot variability in the isoform content and, although the variability is within the set specifications for lot release, made attempts to gain mechanistic insight by isolating and characterizing the individual isoforms. Matrix-assisted laser desorption/ionization (MALDI) and liquid chromatography (LC)/mass spectrometry (MS)/MS analyses of the isolated isoforms indicate that this variability is caused by sialic acid content, as well as truncation of C-terminal lysine of the individual isoforms. Sialidase and carboxypeptidase treatment of the product confirm the observations made by MALDI and LC/MS/MS.